1. Introduction 1.1 Market Definition 2. Research Methodology 3. Executive Summary 4. Key Inferences 5. Market Overview 5.1 Current Market Scenario 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Consumers 5.2.3 Threat of New Entrants 5.2.4 Threat of Substitute Product and Services 5.2.5 Competitive Rivalry within the Industry 5.3 Pipeline Analysis 6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC) 6.1 Market Drivers 6.1.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD) 6.1.2 Increasing Invetsments in Biopharmaceutical R&D to Release Novel Disease Therapies 6.1.3 Increasing Awareness Campaigns for DMD 6.2 Market Restraints 6.2.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD 6.2.2 Stringent Regulatory Framework with High Product Cost Burden 6.3 Market Opportunities 6.4 Market Key Challenges 7. Market Segmentation 7.1 By Therapeutic Approach 7.1.1 Molecular based Therapeis 7.1.1.1 Mutation Suppression 7.1.1.2 Exon Skipping 7.1.2 Steriod Therapy 7.1.3 Others 7.2 By Treatment Type 7.2.1 Cortecosteriods 7.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 7.2.3 Others 7.3 By End User 7.3.1 Hospitals/Clinics 7.3.2 Ambulatory Centers 7.3.3 Others 7.4 By Geography 7.4.1 North America 7.4.1.1 US 7.4.1.2 Canada 7.4.1.3 Mexico 7.4.2 Europe 7.4.2.1 France 7.4.2.2 Germany 7.4.2.3 UK 7.4.2.4 Italy 7.4.2.5 Spain 7.4.2.6 Rest of Europe 7.4.3 Asia-Pacific 7.4.3.1 China 7.4.3.2 Japan 7.4.3.3 India 7.4.3.4 Australia 7.4.3.5 South Korea 7.4.3.6 Rest of Asia-Pacific 7.4.4 Middle East & Africa 7.4.4.1 GCC 7.4.4.2 South Africa 7.4.4.3 Rest of MEA 7.4.5 South America 7.4.5.1 Brazil 7.4.5.2 Argentina 7.4.5.3 Rest of South America 8. Competitive Landscape 8.1 Mergers & Acquisition Analysis 8.2 Agreements, Collaborations, and Partnerships 8.3 New Products Launches 9. Key Players 9.1 BioMarin 9.2 Bristol-Myers Squibb 9.3 Fibrogen Inc 9.4 Marathon Pharmaceuticals 9.5 Nobelpharma Co., Ltd 9.6 NS Pharma,Inc 9.7 Pfizer Inc. 9.8 PTC Therapeutics 9.9 Santhera Pharmaceuticals 9.10 Sarepta Therapeutics * List Not Exhaustive 10. Future of the Market

BioMarin Bristol-Myers Squibb Fibrogen Inc Marathon Pharmaceuticals Nobelpharma Co., Ltd NS Pharma,Inc Pfizer Inc. PTC Therapeutics Santhera Pharmaceuticals Sarepta Therapeutics